Goldman Sachs raises Abbvie stock price target on growth confidence

AbbVie reported Q1 2026 adjusted EPS of $2.65, beating the $2.59 consensus, and revenue of $15.0B, topping estimates by $300M. Goldman Sachs raised its price target to $244 from $240 while keeping a Neutral rating, citing confidence in Skyrizi and Rinvoq through 2031 and encouraging pipeline data. The stock is still down 9.3% year-to-date, but its 3.4% dividend yield and 13 straight years of dividend increases support the investment case.

Analysis

ABBV is setting up as a classic quality-vs-valuation tension trade: the fundamental story is improving, but the stock is still being anchored by the market’s habit of discounting late-cycle biopharma durability too aggressively. The bigger implication is not just multiple support for ABBV, but a relative-value rotation away from names whose pipelines are more binary and toward cash-generative franchises with visible 3-5 year earnings power. That matters because every incremental proof point around durability of the core immunology portfolio compresses the bear case faster than it expands the bull case.

The second-order readthrough is to JNJ’s oral psoriasis entrant and the broader inflammatory-disease space. A successful oral alternative can slow share gains at the margin, but it can also validate category growth and force incumbents to compete on convenience rather than efficacy alone; that often preserves pricing better than investors expect. The more important competitive risk for ABBV is not near-term share loss, but eventual payer re-bundling and step-edit tightening if multiple high-cost therapies proliferate across adjacent indications.

Catalyst timing is favorable over the next 1-3 quarters: management’s confidence plus upcoming clinical readouts can support multiple expansion before hard revenue inflection is visible in consensus models. The main reversal risk is that the market will eventually demand proof in second-half 2026 quarterly trends, especially if launch or label expansion data disappoints. If the pipeline cadence stumbles, the stock can rapidly revert to a dividend yield story and lose the premium for perceived durability.

The contrarian angle is that the market may be underestimating how much of ABBV’s downside is already embedded after months of underperformance, while simultaneously overestimating how quickly new competitors can dislodge entrenched prescriber habits. In that framing, this is less a secular growth trade and more a mean-reversion setup with a free option on pipeline upside. The opportunity is to own the cash flow while the market re-rates confidence in the growth bridge.

Key Decisions for Investors

• Go long ABBV for a 1-3 month tactical relief move into the next catalyst window; target 8-12% upside with a 4-5% downside stop if quarterly commentary fails to improve.
• Pair trade: long ABBV / short JNJ on a 2-4 month horizon to express relative durability in immunology execution versus the market’s assumption that the new oral entrant captures disproportionate share.
• Use a covered-call structure on ABBV for income-focused accounts over the next 1-2 earnings cycles; the dividend floor reduces carry cost while capping exposure to a near-term multiple rerate.
• If ABBV rallies into readout dates, monetize into strength rather than chase; the setup is best for pre-data positioning, not post-data momentum, because expectations will climb faster than fundamentals.
• For event-driven accounts, consider a modest call spread in ABBV expiring after the next pipeline/quarterly update to capture upside convexity with defined risk.